(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid,
(2E,4E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid,
3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid,
NIK-333,
peretinoin,
Peretinoin,
81485-25-8,
Polyprenoic acid,
Acyclic retinoid,
NIK-333,
(2E,4E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid,
UNII-11ALM7A4RV,
CCRIS 9040,
E 5166,
3,7,11,15-Tetramethyl-2,4,6,10,14-hexadecapentaenoic acid,
11ALM7A4RV,
E-5166,
(all-E)-3,7,11,15-Tetramethyl-2,4,6,10,14-hexadecapentaenoic acid,
2,4,6,10,14-Hexadecapentaenoic acid, 3,7,11,15-tetramethyl-, (all-E)-,
Peretinoin [INN],
AK162192,
Peretinoin (JAN),
AC1O5OHU,
(2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapentaenoic acid,
SCHEMBL431954,
NIK333,
4,5-Didehydrogeranylgeranic acid,
UUBHZHZSIKRVIV-KCXSXWJSSA-N,
BCP24299,
MFCD01742209,
NK-333,
ZINC30691356,
AKOS024463297,
CS-5529,
LS-74863,
SC-74158,
AX8148601,
HY-100008,
ST24033963,
D06406,
Peretinoin (oral),
TMHDP,
Peretinoin (oral), Kowa,
D05TOJ,
C20-H30-O2,
CID6437836,
E5166,
C034534,
C487689,
3,7,11,15-tetramethylhexadeca-2,4,6,10,14-pentaenoic acid,
3,7,11,15-tetramethyl-trans-2,4,6,10,14-hexadecapentaenoic acid,
Peretinoin (oral formulation, hepatocellular carcinoma), Kowa Pharmaceutical,